KS
Therapeutic Areas
IO Biotech Pipeline
| Drug | Indication | Phase |
|---|---|---|
| IO102-IO103 (Cylembio®) + pembrolizumab | First-line Advanced Melanoma | Phase 3 |
| IO102-IO103 + pembrolizumab | Advanced Melanoma | Phase 1/2 |
| IO112 | Solid Tumors | Pre-clinical |
Leadership Team at IO Biotech
MZ
Mai-Britt Zocca, Ph.D.
Founder, President & Chief Executive Officer
AS
Amy Sullivan, M.B.A.
Chief Financial Officer
DS
Devin Smith
General Counsel
FM
Faiçal Miyara, Ph.D.
Chief Business Officer
MS
Marjan Shamsaei, Pharm.D.
Senior Vice President Commercial and Portfolio Lead
PH
Peter Hirth, Ph.D.
Chairman of the Board of Directors
HC
Helen Collins, M.D.
Member of the Board of Directors
CE
Christian Elling, Ph.D.
Member of the Board of Directors
HH
Heidi Hunter
Member of the Board of Directors
DV
David V. Smith, M.B.A.
Member of the Board of Directors